Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...
President Obama in his State of the Union address has called for the power to personally make stronger trade agreements – bringing divisive EU deal TTIP closer to adoption and angering campaigners for drugs access.
MedImmune’s neurodegenerative disease partnership with the University of Cambridge is about working with “great scientists with great brains” according to a spokeswoman for parent company, AstraZeneca.
In direct opposition to a petition raised by GPhA (Generic Pharmaceutical Association) and Novartis, AbbVie, Genentech and Amgen are all looking for the US FDA to call for new non-proprietary names for biosimilars.
Biopharmas should stop green lighting safe, mediocre candidates and focus on developing drugs that are genuine scientific breakthroughs to control spiralling R&D costs, according to industry guru Bernard Munos.
Preclinical Oncology Services Limited (Precos) will to work with discovery services firm Argenta Discovery on cancer drug development projects under a revised collaboration agreement announced late yesterday.
AstraZeneca (AZ) has become the latest company to enter into a research collaboration with Jubilant, with the companies initially focusing on delivering preclinical candidates in the neuroscience area.
The use of disposable manufacturing equipment in pharmaceutical
production and greater need for containment equipment were
recurring themes at the Interphex show in Philadelphia last week,
and both were addressed by new equipment...
KS Avicenna, the Canadian unit of KS Biomedix of the UK, launched a
newly expanded contract biopharmaceutical manufacturing facility in
Canada, to service both North American and European clients, at the
start of the BIO 2003 meeting,...
The bulk of biotech companies are firmly rooted towards the foot of
the ladder of corporate evolution. Precious few can realistically
claim to be at the top end of the evolutionary scale with full
R&D capabilities, global reach...